39 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
independently or in collaboration with potential partners. We have employed a targeted commercial infrastructure to promote access to vilobelimab through centers
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
of financial statements in conformity with IFRS and to maintain asset accountability; (iii) access to assets is permitted only in accordance … of formation and domicile of the Company for the enforcement of their respective rights under this Agreement and the Placement Shares and such access
6-K
EX-99.2
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
in the areas of sales, sales operations, marketing, market access, distribution, medical affairs and others. In addition, we are expanding
6-K
EX-99.3
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
-in details to access the meeting.
Capital One Securities Dermatology Panel on May 14, 2024
InflaRx will also participate in the Capital One Securities
6-K
EX-99.1
bn2fhm51d0b
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
o7rr1e4 hoqx
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.1
p96qwl2r1i
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.1
iogplcb9n5
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
2dkd09wzxt4
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
6tihg
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
6-K
EX-99.2
tb1qrrl
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.3
c7lk4twz
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.2
kf37 r3vwfc3xq
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
v3m5o zffer513a46q
13 Apr 23
Current report (foreign)
4:01pm
424B5
soym 8rsrn3jyycg
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
8fed n7ypyknt7ip3j2j
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
iuig9jp
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.1
dby20gbtyzemf1cks
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-10.1
nqji n1013g2
21 Dec 22
Current report (foreign)
7:45am